培美曲塞二钠治疗老年中晚期非小细胞肺癌的近期疗效分析  

Clinical observation of pemetrexed in treating elder advanced non-small cell lung cancer

作　　者：王巍炜[1] 王前[1] 陈楠[1] 李高峰[1] 

机构地区：[1]云南省肿瘤医院胸外科,昆明650118

出　　处：《中国实用医药》2008年第15期78-79,共2页China Practical Medicine

摘　　要：目的观察培美曲塞联合顺铂治疗老年中晚期非小细胞肺癌（NSCLC）的临床疗效和毒性反应。方法34例Ⅲ-Ⅳ期NSCLC患者均经病理组织学和（或）细胞学检查确诊。培美曲塞联合顺铂治疗后评价疗效。结果34例患者均可评价,获得完全缓解0CR3例,部分缓解PR12例,有效率为44.1%（15/34）。最主要的毒副反应为白细胞及血小板降低,但均可耐受。结论培美曲塞联合顺铂治疗老年中晚期NSCLC有较好疗效,可明显改善患者生存质量,,毒副反应轻,易于耐受。Objective To evaluate the clinical effect and toxieity of pemetrexed in treating elder advanced non-small cell lung cancer（NSCLC）.Methods 34 patients with advanced NSCLC diagnosed by pathology or cytology were enrolled into the study.The patients received and were evaluated effect after 2~4 cycles.Results Complete remission （CR）was observrd in 3 cases and PR in 12 cases,the total response rate was 44.1%（15/34）.1year survival rate was 47.1%（16/34）.The main side effects were leucopenia and thrombocytopenia,but they were tolerable.Conclusion The regimen of pemetrexed plus cisplation is effective,safe and well-tolerable in the treatment of elder advanced NSCLC.It significantly prolong the patients,survival time.

关 键 词：非小细胞肺癌 培美曲塞 化疗 老年人 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]